Insmed, Inc. $INSM Shares Bought by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP increased its stake in Insmed, Inc. by 19.4%, acquiring an additional 175,000 shares, bringing its total ownership to approximately 1,075,000 shares.
• Several hedge funds have also boosted their holdings in Insmed, with some notable increases, such as Cullen Frost Bankers Inc. increasing its stake by 164.9% during the first quarter.
• Despite an increase in quarterly revenue by 18.9% year-over-year, Insmed reported a loss of ($1.70) earnings per share for the last quarter, missing analyst estimates.

Vestal Point Capital LP grew its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 19.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,075,000 shares of the biopharmaceutical company's stock after buying an additional 175,000 shares during the period. Insmed accounts for about 5.9% of Vestal Point Capital LP's holdings, making the stock its 3rd biggest holding. Vestal Point Capital LP owned 0.59% of Insmed worth $82,012,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of INSM. Nuveen LLC acquired a new stake in Insmed during the first quarter worth about $88,351,000. Brown Advisory Inc. acquired a new stake in Insmed during the fourth quarter worth about $45,773,000. Duquesne Family Office LLC increased its position in Insmed by 2,867.4% during the fourth quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock worth $40,973,000 after purchasing an additional 573,470 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in Insmed during the first quarter worth about $37,214,000. Finally, Wellington Management Group LLP increased its position in Insmed by 62.5% during the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company's stock worth $93,274,000 after purchasing an additional 470,401 shares during the last quarter.

Insmed Stock Up 1.8%

Shares of INSM stock traded up $2.57 during trading on Friday, reaching $145.10. The company's stock had a trading volume of 2,532,328 shares, compared to its average volume of 2,914,153. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company has a market capitalization of $30.67 billion, a price-to-earnings ratio of -25.41 and a beta of 0.97. The stock's 50-day moving average price is $114.64 and its 200 day moving average price is $89.66. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same quarter in the prior year, the firm earned ($1.94) EPS. The firm's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. The trade was a 44.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 6,865 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 535,320 shares of company stock worth $54,581,793. 3.00% of the stock is owned by insiders.

Analysts Set New Price Targets

INSM has been the subject of several research analyst reports. The Goldman Sachs Group increased their target price on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. UBS Group lifted their price target on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Jefferies Financial Group lifted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Leerink Partners lifted their price target on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Finally, Wells Fargo & Company lifted their price target on shares of Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a research report on Wednesday. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $134.79.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.